Forecast & Rating14 analysts currently cover Caris Life Sciences, with about 71.4% giving a positive rating — meaning they expect the stock to rise. The average price target is $28.15, about 12.8% downside from the current price of $32.27. Price targets span a fair range, indicating some disagreement among institutions. For you, this means most professionals who study Caris Life Sciences closely still see room for the stock to rise. Data as of Sep 22, 2026; for reference only and not investment advice.
Sep 22, 2026Price forecast
$28.15-12.76%
Forecast & RatingBuy
14analysts
- Strong buy64.29%
- Buy7.14%
- Hold28.57%
- Sell0.00%
- Strong sell0.00%
Target price forecast
Forecast dateSep 24, 2026
Forecast met52.5%
Stock price$32.27
Avg. target$28.2
High target$36
Low target$22
Analyst ratings
Strong buy
Buy
Hold
Sell
Strong sell
Source: S&P Global
This information is for reference only and is not investment advice.